Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
暂无分享,去创建一个
R. Szász | D. Alpár | Z. Pauker | T. Masszi | C. Bödör | G. Mikala | G. Barna | P. Farkas | J. Demeter | A. Matolcsy | A. Masszi | M. Egyed | L. Lévay | Tibor Nagy | Z. Nagy | M. Plander | A. Sulák | Hussain Alizadeh | L. Kotmayer | Z. Kohl | R. Kiss | A. Balogh | P. Pettendi | L. Hegyi | T. László | J. Weisinger | Stefánia Gróf | L. Gergely | L. Levay
[1] R. Moia,et al. MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL. , 2022, Blood.
[2] S. Slager,et al. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia , 2022, British journal of haematology.
[3] S. Bens,et al. Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia , 2022, HemaSphere.
[4] Matthew E. Ritchie,et al. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy , 2022, Blood.
[5] R. Herwig,et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies , 2022, Blood.
[6] U. Jaeger,et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab , 2022, Blood.
[7] E. Thompson,et al. Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors , 2021, Blood advances.
[8] M. Hallek,et al. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures , 2021, American journal of hematology.
[9] E. Thompson,et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition , 2021, Blood advances.
[10] P. Csermely,et al. Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy , 2021, British journal of haematology.
[11] V. Seshan,et al. Tumor Targeted Nanoparticles Improve Therapeutic Index of BCL2 and MCL1 dual inhibition. , 2020, Blood.
[12] K. Nasserinejad,et al. Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. , 2020, Blood.
[13] U. Jaeger,et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Kipps,et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. , 2020, The Lancet. Oncology.
[15] A. Zelenetz,et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. , 2020, Blood advances.
[16] A. Roberts,et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. , 2020, Blood.
[17] J. Byrd,et al. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. , 2020, Blood.
[18] J. Byrd,et al. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study , 2020, Clinical Cancer Research.
[19] E. Thompson,et al. Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. , 2020, Blood.
[20] P. Blombery. Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease , 2020, Leukemia & lymphoma.
[21] J. Waring,et al. Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy , 2019, Blood.
[22] E. Thompson,et al. Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax , 2019, Blood.
[23] M. Peifer,et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.) , 2019, Haematologica.
[24] Christopher J. Ott,et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. , 2019, Cancer cell.
[25] L. Bullinger,et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia , 2019, Haematologica.
[26] J. Gribben,et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Kipps,et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. , 2019, The New England journal of medicine.
[28] E. Thompson,et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. , 2018, Cancer discovery.
[29] F. Bosch,et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. , 2018, Blood.
[30] R. Greil,et al. Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study , 2018, Blood.
[31] M. Davids,et al. Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) , 2018, Blood.
[32] Jean Louis Fournier,et al. Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next‐generation sequencing , 2018, Human mutation.
[33] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.
[34] A. Zelenetz,et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States , 2018, Haematologica.
[35] G. Gordon,et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Jeffrey A Jones,et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. , 2018, Blood.
[37] Marco Montillo,et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2018, The New England journal of medicine.
[38] M. Peifer,et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia , 2018, Nature Communications.
[39] K. Stamatopoulos,et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation , 2018, Leukemia.
[40] Jeffrey A Jones,et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. , 2018, The Lancet. Oncology.
[41] B. Cheson,et al. Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients , 2017 .
[42] S. Lade,et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. , 2017, Blood.
[43] K. Stamatopoulos,et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations , 2017, Leukemia.
[44] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[45] L. Laurenti,et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. , 2016, Blood.
[46] T. Kipps,et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.
[47] R. Emerson,et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study , 2015, Leukemia.
[48] J. Martinez-Climent,et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. , 2014, Blood.
[49] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[50] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.